Agios Pharmaceuticals Inks Global License Deal for Cevidoplenib

Agios Pharmaceuticals Inc. (AGIO) on June 1, 2026, entered into a global license agreement for cevidoplenib, an investigational therapy. Financial details of the transaction were not immediately disclosed. The agreement grants the company worldwide rights to develop and commercialize the asset. Shares of Agios edged higher in early trading following the announcement.